Shoulder Innovations (SI) has received the US Food and Drug Administration's 510(k) clearance for the N-22 Humeral Head titanium implant for patients with metal hypersensitivity, the company said late Thursday.
The company said it also initiated the product's full commercial launch.
The implant is designed for anatomic total shoulder arthroplasty procedures and complements the company's N-22 Glenosphere implant used in reverse total shoulder arthroplasty procedures, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.